Compare · OBIO vs RGC
OBIO vs RGC
Side-by-side comparison of Orchestra BioMed Holdings Inc. (OBIO) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OBIO and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $4.72B, about 13.7x OBIO ($345.0M).
- OBIO has been more active in the news (4 items in the past 4 weeks vs 1 for RGC).
- OBIO has more recent analyst coverage (10 ratings vs 0 for RGC).
- Company
- Orchestra BioMed Holdings Inc.
- Regencell Bioscience Holdings Limited
- Price
- $5.43-5.48%
- $9.62+3.05%
- Market cap
- $345.0M
- $4.72B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 4
- 1
- Recent ratings
- 10
- 0
Latest OBIO
- Officer Sherman Darren sold $95,400 worth of shares (15,000 units at $6.36) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,119,402 units (SEC Form 4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
- Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
- Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
- Officer Hochman David P covered exercise/tax liability with 6,566 shares, decreasing direct ownership by 0.31% to 1,067,463 units (SEC Form 4) (tax withholding)
- Orchestra BioMed upgraded by BTIG Research with a new price target
- Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Officer Hochman David P bought $47,900 worth of shares (10,000 units at $4.79), increasing direct ownership by 0.94% to 1,070,746 units (SEC Form 4)
- Officer Sherman Darren sold $74,100 worth of shares (15,000 units at $4.94) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,134,402 units (SEC Form 4)
Latest RGC
- SEC Form 20-F filed by Regencell Bioscience Holdings Limited
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited